RRMS patients exhibit significant upregulation of NLRP3, ASC, and caspase‐1, as well as a decrease in serum TGF‐β1 and an increase in IL‐1β levels [45]. This evidence concerns the gene IL1B and relapsing-remitting multiple sclerosis.